HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating for BioCardia (NASDAQ:BCDA) and maintained a price target of $25.
October 28, 2024 | 3:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for BioCardia, maintaining a $25 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $25 price target by a reputable analyst suggests a positive outlook for BioCardia. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100